TY - JOUR
T1 - Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer
T2 - A preliminary report
AU - Vokes, E. E.
AU - Rosenberg, R.
AU - Jahanzeb, M.
AU - Craig, J.
AU - Gralla, R.
AU - Belani, C.
AU - Jones, S.
AU - Bigley, J.
AU - Hohneker, J.
AU - Gralla,
AU - O'Rourke,
AU - Crawford,
AU - Tuttle,
AU - Viallet,
AU - Moinpour,
PY - 1994
Y1 - 1994
N2 - Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.
AB - Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.
UR - http://www.scopus.com/inward/record.url?scp=0028105087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028105087&partnerID=8YFLogxK
M3 - Article
C2 - 7973767
AN - SCOPUS:0028105087
SN - 0093-7754
VL - 21
SP - 35
EP - 41
JO - Seminars in oncology
JF - Seminars in oncology
IS - 5 SUPPL. 10
ER -
